Alan Harvey will discuss neurotrauma research, Cliff Richard and the role of music in the evolution of the modern mind at the ANS meeting this week.

Benitec (ASX:BLT) has appointed former Axon Instruments VP Michael Catelani as executive director and Boron Molecular founder Peter Francis as non-executive director.

Clinical Cell Culture's (ASX:CCE) co-founder Prof Fiona Wood will step down from the company's board on December 31. She will remain as a consultant, an R&D partner through her research vehicle the McComb Foundation, and a substantial shareholder.

Veteran biotech investment group Circadian Technologies (ASX:CIR) has posted an AUD$21.77 million profit before tax for the 2004/05 financial year, up from $5.8 million for the previous corresponding year.

Ruth Beran discovers how one of Australia's great bioentrepreneurs has moved from inspiring shareholders to inspiring a nation.

Australian Biotechnology News journalist Ruth Beran asked Axon Instruments founder Alan Finkel if he had any advice for Australian companies with an eye on the world stage. Here is his reply.

Bioscience entrepreneurs, including Axon Instruments founder Alan Finkel and Fiona Wood and Marie Stoner of Clinical Cell Culture, have dominated the winners' circle at this year's ATSE Clunies Ross Awards.

Researchers at the Queensland Brain Institute and the University of Melbourne have identified a molecule which they believe may play a crucial role in preventing spinal cord regeneration.

Long-time biotech investment group Circadian (ASX: CIR) is planning to return AUD$0.50 cents per share to investors after posting a $5.8 million profit for the 2003-2004 financial year with an even better profit forecast for next year.

Long-time biotech investment group Circadian (ASX: CIR) is planning to return AUD$0.50 cents per share to investors after posting a $5.8 million profit for the 2003-2004 financial year with an even better profit forecast for next year.